A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

The drug — the brand name for the GLP-1 agonist semaglutide — “significantly reduced weekly alcohol craving,” according to a study published Wednesday, Feb. 12, in the Journal of the ...

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...

Half received semaglutide, a type of GLP-1 receptor agonist, while the other half received no treatment. Over the nine-week trial, participants taking semaglutide started at a dose of 0.25 mg per ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally ... compared to other antidiabetic drugs. 4 These observations were based on 100 million patient records ...

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor mimicking its activity. GLP-1 is an incretin hormone and enterogastrone that stimulates insulin ...

At least nine patients using the glucagon-like peptide 1 (GLP-1 ... patients (mean age, 57.4 years; 56% women) who developed ophthalmic complications while using semaglutide (n = 6) or tirzepatide ...